In a recent study using mice, lab-grown human retinal cells and patient samples, Johns Hopkins Medicine scientists say they found evidence of a new pathway that may contribute to degeneration of the light sensitive tissue at the back of the eye. The findings, they conclude, bring scientists a step closer to developing new drugs for a central vision-destroying complication of diabetic eye disease that affects an estimated 750,000 Americans.
The Johns Hopkins research team focused on diabetic macular edema, a form of swelling and inflammation that occurs in people with diabetes when blood vessels in the eye leak their fluids into the portion of the retina that controls detailed vision.
Current therapies for this disease block the protein VEGF, which contributes to abnormal blood vessel growth. However, because the treatment is not adequate for more than half of patients with diabetic macular edema, investigators have long suspected that more factors drive vision loss in these patients.
In the new study, the Johns Hopkins researchers say they found compelling evidence that angiopoietin-like 4 is at play in macular edema. The signaling protein is already well known to be a blood vessel growth factor with roles in heart disease, cancer and metabolic diseases, of which diabetes is one.
A report on the findings was published Sept. 23 in The Journal of Clinical Investigation.
Akrit Sodhi, M.D., Ph.D., associate professor of ophthalmology at the Johns Hopkins University School of Medicine and the Johns Hopkins Wilmer Eye Institute, in collaboration with Silvia Montaner, Ph.D., M.P.H., at the University of Maryland, led the research team and was intrigued by angiopoietin-like 4 after finding, in previous studies, elevated levels of this protein in the eyes of people with a variety of vision-related diseases.
In the new study, Sodhi and his team found that angiopoietin-like 4 acts both independent of, and synergistically with, VEGF activity, and they identified a potential way to block it.
The investigators made their discoveries by exposing human blood vessel tissue cells grown in the lab to low levels of VEGF and angiopoietin-like 4. Knowing that low levels of these factors individually did not generally create an effect, the researchers were surprised to find that in combination, low-level VEGF and low-level angiopoeitin-like 4 had a synergistic effect on vascular cell permeability, and doubled the leakage from retinal vessels in mice.
“This told us that you can have subthreshold levels of both molecules, where neither alone is enough to do anything, but together, produce a huge effect,” says Sodhi.
The amplifying effect led the researchers to believe that VEGF and angiopoietin-like 4 might share a protein receptor within vascular cells.
However, similar experiments revealed that angiopoietin-like 4 also increases blood vessel formation independently of VEGF. “This could explain why some patients continue to experience vision loss despite treatment with current anti-VEGF therapies,” says Sodhi.
To test this, the team looked to see whether the angiopoietin-like 4 protein bound to one of VEGF’s receptors in lab-grown human vascular cells. They found that angiopoietin-like 4 did not bind to the classic VEGF receptor that is a target of current anti-VEGF medicines, but another less studied one called neuropilin.
With the newly identified receptor, the researchers next sought to learn whether a lab-grown version of the receptor could block angiopoietin-like 4 before it was able to interact with blood vessel cells.
To do that, they injected a soluble fragment of the neuropilin receptor into the eyes of mice pharmacologically treated to mimic human diabetes, resulting in a twofold increase in retinal vascular leakage. The treated diabetic mice showed approximately half of the blood vessel leakage as mice who did not receive the treatment, similar to the nondiabetic mice.
To further explore the new receptor-based treatment’s potential value for human patients, the researchers grew human blood vessel cells in the lab in fluid samples collected from the eyes of patients with diabetic macular edema, to replicate the conditions and growth factors found naturally inside of the patients’ eyes.
One group of such cells was exposed to the soluble receptor neuropilin. The researchers say they observed a marked decrease in the diabetic macular edema cells treated with the receptor compared to untreated cells.
“This gives us some confidence that this approach will work in human eyes as well,” says Sodhi, although he cautions that clinical use of a treatment based on their findings will require many more years of research.
Next, the researchers hope to take a look at the molecular interactions between angiopoietin-like 4 and the neuropilin receptor. Doing so, says Sodhi, will allow them to create a refined match that can bind up as much vision-threatening angiopoietin-like 4 in the eye as possible.
Sodhi also hopes the team’s discovery will have value in treating cancer and cardiovascular disease, the courses of which also are influenced by uncontrolled blood vessel growth.
Other researchers involved in this study include Monika Deshpande, Kathleen Jee and Jordan Vancel of the Johns Hopkins University School of Medicine, and Tao Ma, Deepak Menon, Aumreetam Dinabandhu, Daoyuan Lu and Silvia Montaner of the University of Maryland.
This work was supported by the National Eye Institute (5R01EY025705) and Research to Prevent Blindness.
Story Source:
Materials provided by Johns Hopkins Medicine. Note: Content may be edited for style and length.
Journal Reference:
- Akrit Sodhi, Tao Ma, Deepak Menon, Monika Deshpande, Kathleen Jee, Aumreetam Dinabandhu, Jordan Vancel, Daoyuan Lu, Silvia Montaner. Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema. Journal of Clinical Investigation, 2019; 129 (11): 4593 DOI: 10.1172/JCI120879
Source: sciencedaily.com
Johns Hopkins Medicine. “Helper protein worsens diabetic eye disease: Blocking second protein could lead to better treatment.” ScienceDaily. ScienceDaily, 27 November 2019. <www.sciencedaily.com/releases/2019/11/191127090230.htm>.
For more helpful eye care and vision care tips, please visit our main blog page.
Natural alternatives to antidepressants
Step Into a World of Wonder: A Seamless Journey with The Truffle Experience
At this store, we are dedicated to providing you with a smooth, secure, and magical shopping experience — from browsing our collection to receiving your carefully prepared package. Each step is designed with simplicity, trust, and a touch of magic in mind.
How to Order from Magic Truffle Shrooms Brand
Explore Our Magical Collection – Browse through our premium line of psilocybin-infused products on the shop page.
Choose Your Adventure – Select your preferred strain, amount, and form, such as chocolates, capsules or gummies.
Review and Checkout – Make sure everything is correct in your cart, then proceed to checkout by entering your shipping details.
Secure Payment Process – Once your order is placed, you will receive clear payment instructions. After confirmation, we begin preparing your shipment with care.
Track Your Package – You will be sent a tracking number so that you can follow your mystical delivery all the way to your door.
Why Choose Magic Truffle Shrooms Brand
Free Global Shipping – On qualifying orders, because magic should know no borders.
24 7 Customer Support – Our team is always ready to assist you.
Money Back Guarantee – Shop with confidence knowing we offer a full refund if needed.
Our Top Rated Products
Amazonian – A powerful strain known for deep and life changing experiences.
Mazatapec – Respected for its spiritual depth and inner exploration.
Penis Envy – Strong and intense, ideal for experienced users.
Dancing Bear – Lively and uplifting, perfect for joyful journeys.
Each item comes in multiple forms — choose from chocolates, capsules, gummies and more to match your taste and needs.
Explore Our Full Range
All of our artisanal organic products are lab tested and made right here in Santa Cruz, California. The current catalog includes:
4 PO DMT
Magic Mushroom Chocolate Bars (Custom Flavor)
Microdose Capsules – Ideal for gentle enhancement and focus.
Psilocybin Gummies and Syrup – A tasty and fun way to explore.
The Power of Psilocybin Perfected
Psilocybin is a sacred natural compound that has fascinated scientists, shamans and seekers throughout history. At Magic Truffle Shrooms Brand, we guarantee accurate dosing, top tier quality and predictable effects — whether you’re exploring spirituality, boosting creativity or starting a personal journey of growth.
Every chocolate bar, capsule and edible is made with purpose, helping you dive into the world of psilocybin safely, confidently and joyfully.
Ready to Begin Your Magical Adventure
Enter the realm of Magic Truffle Shrooms Brand — where excellence, reliability and enchantment come together seamlessly.
evernote.us.com nên cải thiện toàn diện nếu muốn giữ người dùng
This is a topic that is near to my heart… Best wishes! Where can I find the contact details for questions?
Spot on with this write-up, I honestly think this amazing site needs a great deal more attention. I’ll probably be returning to see more, thanks for the info!
decomania
Voici un spin-tax de haute qualité pour votre texte en français, respectant toutes vos consignes :
Alors que le média spécialisé Decomania analyse les innovations dans le domaine fintech, un doute subsiste : Quantum AI 2025 incarne-t-il une avancée réelle ou simplement une initiative prometteuse ?
Mécanisme et Promesses : Quel est le Principe de Cette Plateforme ?
Quantum AI 2025 se définit comme un système de investissement algorithmique combinant IA et quantum computing. D’après ses concepteurs, cette technologie permettrait :
Une évaluation poussée des marchés (crypto, valeurs mobilières, Forex).
Une gestion automatisée du risque pour améliorer les résultats.
Une interface intuitive, conçu pour les investisseurs tous niveaux.
Toutefois, aucun audit externe ne confirme formellement ces allégations, et les témoignages demeurent mitigés.
Points à Vérifier D’après Decomania
Notre examen révèle plusieurs éléments à évaluer avant de investir :
Plusieurs URLs géolocalisées (crypto-bank.fr) – Un usage répandu, mais qui peut rendre difficile la vérification.
Opacité relative – Peu d’informations techniques figurent sur les algorithmes utilisés.
Performances inégales – Certains utilisateurs rapportent des résultats concluants, tandis qu’ plusieurs rapportent des difficultés techniques.
Suggestions pour les Traders
Favoriser les plateformes régulées (CySEC) pour une meilleure protection.
Expérimenter en compte test avant toute mise de fonds.
Comparer avec des alternatives (à l’image de les outils offerts par eToro).
Conclusion : Une Solution à Surveiller avec Prudence
Quantum AI 2025 avance une technologie de pointe, mais son efficacité réelle requièrent davantage des confirmations pratiques. Dans l’attente de davantage d’informations, une approche mesurée est recommandée.
Thank you so much!